title: Cleavage and reduced CD36 ectodomain density on heart and spleen macrophages in the spontaneously hypertensive rat.
abstract: Metabolic disease is accompanied by a range of cellular defects ("comorbidities") whose origin is uncertain. To investigate this pathophysiological phenomenon we used the Spontaneously Hypertensive Rat (SHR), which besides an elevated arterial blood pressure also has many other comorbidities, including a defective glucose and lipid metabolism. We have shown that this model of metabolic disease has elevated plasma matrix metalloproteinase (MMP) activity, which cleaves the extracellular domain of membrane receptors. We hypothesize here that the increased MMP activity also leads to abnormal cleavage of the scavenger receptor and fatty acid transporter CD36. To test this idea, chronic pharmaceutical MMP inhibition (CGS27023A) of the SHR and its normotensive control, the Wistar Kyoto Rat (WKY), was used to determine if inhibition of MMP activity serves to maintain CD36 receptor density and function. Surface density of CD36 on macrophages from the heart, spleen, and liver was determined in WKY, SHR, CGS-treated WKY (CGS WKY), and CGS-treated SHR (CGS SHR) by immunohistochemistry with an antibody against the CD36 ectodomain. The extracellular CD36 density was lower in SHR heart and spleen macrophages compared to that in the WKY. MMP inhibition by CGS served to restore the reduced CD36 density on SHR cardiac and splanchnic macrophages to levels of the WKY. To examine CD36 function, culture assays with murine macrophages (RAW 264.7) after incubation in fresh WKY or SHR plasma were used to test for adhesion of light-weight donor red blood cell (RBC) by CD36. This form of RBC adhesion to macrophages was reduced after incubation in SHR compared WKY plasma. Analysis of the supernatant macrophage media by Western blot shows a higher level of CD36 extracellular protein fragments following exposure to SHR plasma compared to WKY. MMP inhibition in the SHR plasma compared to untreated plasma, served to increase the RBC adhesion to macrophages and decrease the number of receptor fragments in the macrophage media. In conclusion, these studies bring to light that plasma in the SHR model of metabolic disease has an unchecked MMP degrading activity which causes cleavage of a variety of membrane receptors, including CD36, which attenuates several cellular functions typical for the metabolic disease, including RBC adhesion to the scavenger receptor CD36. In addition to other cell dysfunctions chronic MMP inhibition restores CD36 in the SHR.
authors.affiliation: Department of Bioengineering, Jacobs School of Engineering, Institute of Engineering in Medicine, University of California San Diego, La Jolla, CA 92093, USA. Electronic address: msantamariaaviles@gmail.com.
authors.forename: Marco H
authors.initials: MH
authors.lastname: Santamaria
authors.affiliation: Department of Bioengineering, Jacobs School of Engineering, Institute of Engineering in Medicine, University of California San Diego, La Jolla, CA 92093, USA. Electronic address: vistacove2009@gmail.com.
authors.forename: Angela Y
authors.initials: AY
authors.lastname: Chen
authors.affiliation: Department of Bioengineering, Jacobs School of Engineering, Institute of Engineering in Medicine, University of California San Diego, La Jolla, CA 92093, USA. Electronic address: jcchow09@gmail.com.
authors.forename: Jason
authors.initials: J
authors.lastname: Chow
authors.affiliation: Department of Bioengineering, Jacobs School of Engineering, Institute of Engineering in Medicine, University of California San Diego, La Jolla, CA 92093, USA. Electronic address: dianamunoz07@yahoo.com.
authors.forename: Diana C
authors.initials: DC
authors.lastname: Muñoz
authors.affiliation: Department of Bioengineering, Jacobs School of Engineering, Institute of Engineering in Medicine, University of California San Diego, La Jolla, CA 92093, USA. Electronic address: gwss@bioeng.ucsd.edu.
authors.forename: Geert W
authors.initials: GW
authors.lastname: Schmid-Schönbein
mesh_terms: D000818:Animals; D062186:Arterial Pressure; D018955:CD36 Antigens / Q000187:drug effects / Q000378:metabolism*; D002478:Cells, Cultured; D004195:Disease Models, Animal; D015536:Down-Regulation; D004912:Erythrocytes / Q000378:metabolism; D006973:Hypertension / Q000201:enzymology* / Q000276:immunology / Q000503:physiopathology; D008264:Macrophages / Q000201:enzymology* / Q000276:immunology; D008297:Male; D061965:Matrix Metalloproteinase Inhibitors / Q000494:pharmacology; D020782:Matrix Metalloproteinases / Q000378:metabolism*; D009206:Myocardium / Q000201:enzymology* / Q000276:immunology; D059748:Proteolysis; D011918:Rats, Inbred SHR; D011921:Rats, Inbred WKY; D013154:Spleen / Q000187:drug effects / Q000201:enzymology* / Q000276:immunology
chemical_list: D018955:CD36 Antigens; D061965:Matrix Metalloproteinase Inhibitors; D020782:Matrix Metalloproteinases
keywords: CD36; MMP; MMP inhibitor CGS27023A; Spontaneously Hypertensive Rat (SHR); TIMP